- ￥1100 - 1980
- CUSABIO
- CN
- CSB-PA447621
- 2025年07月15日
- ELISA,IHC;ELISA:1:2000-1:10000,IHC:1:100-1:300
- Rabbit
- Human,Mouse,Rat
企业认证
相关产品推荐更多 >
UNC50抗体UNC50兔多抗抗体Uncoordinated-like protein抗体UNC50 Antibody, Biotin conjugated抗体
￥880
IL6ST抗体IL6ST一抗抗体Oncostatin-M receptor subunit alpha antibody抗体IL6ST Antibody抗体
￥880
TMED3抗体TMED3兔多抗抗体UNQ5357/PRO1078 antibody抗体TMED3 Antibody, FITC conjugated抗体
￥880
LCA5抗体LCA5兔多抗抗体Leber congenital amaurosis 5 protein antibody抗体LCA5 Antibody, Biotin conjugated抗体
￥880
HIPK1抗体HIPK1兔多抗抗体Nuclear body associated kinase 2b antibody抗体HIPK1 Antibody, FITC conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Fusion protein of Human MFAP3L
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
Non-conjugated
- 适应物种：
Human,Mouse,Rat
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
O75121
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA,IHC;ELISA:1:2000-1:10000,IHC:1:100-1:300
- 浓度：
>95%,Antigen affinity purification
- 靶点：
MFAP3L
- 抗体英文名：
MFAP3L Antibody
- 抗体名：
MFAP3L;KIAA0626;HSD-39;HSD39;Microfibrillar-associated protein 3-like;Testis development protein NYD-SP9
- 规格：
100μl/50μl
| 规格： | 100μl | 产品价格： | ￥1980.0 |
|---|---|---|---|
| 规格： | 50μl | 产品价格： | ￥1100.0 |
保存缓冲液
-20℃, pH7.4 PBS, 0.05% NaN3, 40% Glycerol功能
MFAP3L (microfibrillar-associated protein 3-like), also known as HSD39 or testis development protein NYD-SP9, is a 409 amino acid single-pass type I cell membrane protein that contains one Ig-like (immunoglobulin-like) domain. Found primarily in testis, MFAP3L is encoded by a gene that is located on chromosome 4 and is expressed as three isoforms due to alternative splicing events. Representing approximately 6% of the human genome, chromosome 4 contains nearly 900 genes, one of which is the Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease.风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering
Antibodies make up the largest, growing segment of protein therapeutics in the pharmaceutical and biotechnology industries. The development or engineering of therapeutic antibodies is based to a large extent on our knowledge of antibody
Antibody Development and Use in Chromogenic and Fluorescent Immunostaining
Antibody-based detection of protein distribution patterns both in wholemount and on sections revolutionized Xenopus research and ushered in the visual-based era of Xenopus data presentation. The ability to view the distribution of a gene
【翻译】Development trends for monoclonal antibody cancer therapeutics
through either chemical conjugation or genetic engineering22. Development of both types of immunotoxins has posed challenges because the protein toxins can be immunogenic and the drug toxins may lack potency at the doses delivered to the tumour site17. In both cases
技术资料暂无技术资料 索取技术资料
